Last updated 14 days ago

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

1250 patients around the world

Available in Argentina, United States, Brazil

Alnylam Pharmaceuticals

1250Patients around the world

This study is for people with

Rare diseases

Amyloidosis

Requirements for the patient

To 85 Years

All Gender

Medical requirements

: Has documented diagnosis of ATTR amyloidosis with cardiomyopathy including those with hereditary ATTR (hATTR) or wild-type ATTR (wATTR) amyloidosis.
Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF or signs and symptoms that require treatment with a diuretic.
Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) >300 ng/L and <8500 ng/L; In patients with permanent or persistent atrial fibrillation, screening NT-proBNP >600 ng/L and <8500 ng/L.
Patients may be receiving approved TTR stabilizers for ATTR amyloidosis (eg, tafamidis, acoramidis) and may be receiving background therapy for HF at the discretion of the Investigator.

: Has New York Heart Association (NYHA) Class IV HF; or NYHA Class III heart failure AND ATTR Amyloidosis Disease Stage 3.
Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV.
Has an estimated glomerular filtration rate eGFR of <30 mL/min/1.73m^2 at screening.
Has received prior or currently receiving TTR-lowering therapy.

SponsorAlnylam Pharmaceuticals

Study typeInterventional

Conditions

Amyloidosis

Requirements

To 85 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07052903